Servier will acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65 billion, including $1.55 billion upfront and as much as $1.1 billion tied to regulatory and commercial milestones. The centerpiece is sevasemten (EDG-5506), a skeletal myosin inhibitor being evaluated in Becker muscular dystrophy and Duchenne muscular dystrophy. Edgewise’s sevasemten is designed to preserve muscle tissue by limiting contraction-induced damage, with a pivotal program in Becker muscular dystrophy and a Phase 2 study already underway for Duchenne. Servier said it expects to close the transaction in the third quarter of 2026, subject to regulatory clearance and customary conditions. The acquisition expands Servier’s neurology portfolio as it moves to build a broader pipeline in neuromuscular disorders, an area with limited approved therapies and high unmet need.